Business Wire

Third Annual CES Unveiled Paris Kicks off this week as the largest CES Unveiled Event Abroad

Del

The Consumer Electronics Association (CEA) ® is returning to France for the third annual CES Unveiled Paris this Wednesday. At more than twice the size of the 2014 event and with more than 50 exhibitors confirmed, the sold-out event will bring innovative technology companies, top press, buyers, industry analysts and key tech influencers together to highlight and review new products and tech trends originating at CES. CES Unveiled Paris will take place from 2-6 PM, on October 21, at the Pavillon Cambon-Capucines in Paris, France.

“It’s invigorating to see our Paris event become CEA’s largest CES Unveiled event abroad after only three years,” said Gary Shapiro, president and CEO, CEA. “The French technology community is a driving force of innovation in the tech world. We look forward to seeing France’s leading innovators at CES Unveiled Paris this week.”

The event is designated for the press, consumer technology industry analysts, buyers, investors and tech executives. While online registration is closed for the event, attendees may register onsite on the day of the event beginning at 1 PM.

Programming for CES Unveiled Paris will include a CEA Market Research Presentation, a CES press conference, a panel discussion featuring top executives from La Poste, Legrand and Atol focused on tech adaptability in big industry, and conclude with a two-hour exhibition networking reception. Please note that presentations will begin at 2 PM following registration. Doors to the Exhibition Networking Reception will not open until 4 PM following the panel discussion. The event schedule is as follows:

     
1-2 PM:

Registration

2-2:15 PM: Welcome Remarks

Philippe Wahl, Chairman and CEO, La Poste Group

2:15-3 PM: CEA Market Research Presentation

Dr. Shawn DuBravac, CFA, Ph.D., Chief Economist and Sr. Director of Research, CEA

3-3:30 PM: CES Press Conference

Gary Shapiro, President and CEO, CEA

3:30-4 PM:

Panel Discussion: Retailers’ New Paradigm and Challenges

Moderator: François Sorel, Journalist, 01net and BFM

Panelists:

Bruno Barlet, VP France, Legrand

Nathalie Collin, Deputy CEO in charge of Digital Business and Communication of La Poste Group

Fabrice Obenans, Marketing and Communication Director, Atol Les Opticiens

 
4-6 PM:

Exhibition Networking Reception

 

CES Unveiled Paris expects more than 50 exhibiting companies, including:

New this year, CEA is partnering with La Poste, France’s mail service provider, and Business France, a government agency supporting the international development of the French economy. As official partners, La Poste and Business France are committed to bringing innovative technology solutions to legacy industries in France.

CES Unveiled Paris highlights the dynamism of the consumer technology industry, leading up to CES 2016, which will run January 6-9, 2015 in Las Vegas, Nevada. For further information about exhibiting or attending the event, please visit our website.

Note to Editors: The official name of the global technology event is “CES ® .” Please do not use “Consumer Electronics Show” or “International CES” to refer to the event.

About CES:

CES is the world’s gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for more than 40 years—the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. And because it is owned and produced by the Consumer Electronics Association (CEA), the technology trade association representing the $285 billion U.S. consumer electronics industry, it attracts the world’s business leaders and pioneering thinkers to a forum where the industry’s most relevant issues are addressed. Check out CES video highlights. Follow CES online at www.CESweb.org and on social.

About La Poste Group:

La Poste is a limited company in 100 percent public ownership since 1 March 2010 with a unique corporate model structured around five business units: Mail-Parcels-Services, La Banque Postale, The Network La Poste, GeoPost and Digital Services. The Group operates out of 40 countries on 4 continents. La Poste's 17,000 retail outlets make it France's leading local distribution network, each day serving 1.7 million customers. Every year, La Poste delivers 23.5 billion items worldwide (letters, printed ad media and parcels), 6 days a week. In 2013, Le Groupe La Poste generated €22.2 billion in revenues (17.9% outside France) and had a headcount of over 260,000. Le Groupe La Poste's strategic plan, "La Poste 2020: Conquering the Future" outlines its ambitious objective of speeding up development in its five business units and expanding into new territories. La Poste puts human considerations and trust at the centre of customer relations. Greater synergies between its networks, accessible to everyone, everywhere, every day, are helping to make life easier for La Poste's customers. The La Poste digital branch was established in April 2014 and brings together all of the group's digital activities under one roof. It comprises the digital division of La Poste and three BtoB subsidiaries: Docapost (a specialist in the digital transformation of companies), Mediapost Communication (digital media management and data processing) and Start’inPost (an industrial startup accelerator). It employs more than 5,500 people.

About Business France:

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. For further information, please visit: www.businessfrance.fr

UPCOMING EVENTS

  • CES Unveiled Paris
    October 21, 2015, Paris, France
  • CEA Innovate! - Register
    November 8-10, 2015, New York, NY
  • CE Hall of Fame Dinner - Register
    November 9, 2015, New York, NY
  • CES Unveiled New York - Register
    November 10, 2015, New York, NY
  • CES Unveiled Las Vegas
    January 4, 2016, Las Vegas, NV
  • CES 2016 - Register
    January 6-9, 2016, Las Vegas, NV
  • CEA Winter Break
    March 21-24, 2016, Park City, UT
  • CES Asia 2016
    May 11-13, 2016, Shanghai, China

Contact information

Consumer Electronics Association
Allison Fried, 703-907-7603
afried@CE.org
www.CE.org
or
Krista Silano, 703-907-4331
ksilano@CE.org
www.CESweb.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom